Vimseltinib may be promising in treating symptomatic tenosynovial giant cell tumour
1. Tumor response rate at 25 weeks was significantly greater in vimseltinib than placebo. 2. Most adverse events were mild-to-moderate...
1. Tumor response rate at 25 weeks was significantly greater in vimseltinib than placebo. 2. Most adverse events were mild-to-moderate...
1. Return to baseline function was comparable in tenecteplase and standard-of-care groups. 2. More deaths and intracranial hemorrhages were reported...
1. Individuals with elevated fat attenuation index scores without obstructive coronary artery disease had significantly increased rates of major adverse...
1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse...
1. Women in the surgical group reported 2.5 times more spontaneous ovulations than in medical therapy. 2. Those assigned to...
1. Fewer patients in the decompressive craniectomy group had an mRS score of 5-6 compared to medical treatment alone, although...
1. There was no significant difference in metastasis-free survival between the ADT and non-ADT groups over 10 years. 2. Adverse...
1. Clinically relevant bleeding was significantly lower with ticagrelor monotherapy than in the ticagrelor plus aspirin group. 2. Major cardiovascular...
1. Target-vessel failure was significantly lower in the ultrasound-guided group than the angiography-guided group. 2. There was no significant difference...
1. Patients in the PCI group reported significantly lower rates of cardiac death, revascularization, and hospitalization than those in the...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.